Completed PHASE3 INTERVENTIONAL 2-arm NCT01277016

A Trial for Systemic Light-chain (AL) Amyloidosis (EMN-03)

A Randomized Open-label Multicenter Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients With Systemic Light-chain (AL) Amyloidosis

Sponsor: European Myeloma Network B.V.

Conditions AL Amyloidosis

Interventions BMDex

Updated 7 times since 2017 Last updated: Mar 9, 2017 Started: Jan 31, 2011 Primary completion: Feb 29, 2016 Completion: Jul 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates AL Amyloidosis and is currently completed. European Myeloma Network B.V. leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Nov 2024 — Present [monthly]

Completed PHASE3
Sep 2024 — Nov 2024 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Mar 2024 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Mar 2024 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

European Myeloma Network B.V.

Data source: European Myeloma Network B.V.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pavia, Italy